https://www.selleckchem.com/pr....oducts/etomoxir-na-s
We hypothesize that administration of BV can induce a VKH-like uveitis, caused by loss of function of protective CD30 cells present in the uveal tract, possibly aggravated by collateral damage to surrounding CD30 cells and melanocytes, leading to a uveal immune reaction. It is therefore important for the clinicians using BV to be aware of this adverse event. Growing experience with immunotherapy will provide more clinical insights in these complex immune mechanisms in the future. We hypothesize that administration of BV can ind
Like
Comment
Share
